We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
TrovaGene: Trovera Liquid Biopsy Urine Test Results Positive (Revised)
Read MoreHide Full Article
Molecular diagnostic company, TrovaGene Inc. , recently presented clinical results demonstrating the effectiveness of its Trovera non-invasive test in detecting EGFR T790M mutations in the urine of patients with non-small cell lung cancer (NSCLC).
Built upon TrovaGene’s Precision Cancer Monitoring (PCM) platform, Trovera urine and blood-based EGFR, KRAS and BRAF CLIA and CAP-accredited tests are available to oncologists for the detection and monitoring of cancerous tumors.
The presentation demonstrated at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting showed that urine-based biopsy is an effective alternative to plasma or tissue-based tests when it comes to the detection of T790M mutations for targeted therapies.
The presentation showed that urine and plasma tests identified EGFR T790M mutations which tissue tests failed to spot. This is probably due to tumor heterogeneity or inadequate sample quality. Moreover, response rate to therapy, duration of response and progression-free survival of patients positive for T790M in urine was similar to patients who tested positive for T790M in plasma or tissue.
Lung cancer currently accounts for approximately 58% of TrovaGene’s total test volume. The company is planning to publish nine papers across a number of peer-reviewed journals in 2016.
TrovaGene also noted the publication of the first manuscript with a peer-reviewed paper in the oncology journal Cancer Discovery.
The first paper highlighted PCM platform’s ability to confirm BRAF V600E mutational status and to quantitatively assess changes in urinary circulating tumor DNA. The paper concluded that PCM can be used to determine response to novel therapy combining both a BRAF inhibitor and a MEK inhibitor to treat colorectal neuroendocrine tumors.
Of the remaining eight papers, TrovaGene has already submitted three and is in the process to submit another two in the near term.
The recent presentation validates TrovaGene’s claims over the effectiveness of its PCM technology. It is to be noted that the company’s non-invasive, cell-free technology is cost efficient. We feel that the technology can be ancillary to the current standard of tissue biopsy. It can also be performed in patients not fit for a tissue biopsy.
Zacks Rank & Key Picks
Currently, TrovaGene has a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader medical sector include IRadimed (IRMD - Free Report) , Masimo Corp (MASI - Free Report) and Exactech . While Masimo sports a Zacks Rank #1 (Strong Buy), both IRadimed and Exactech carry a Zacks Rank #2 (Buy).
(We have revised this article to correct a mistake. The previous version, published on Jun 7, should not be relied upon.)
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
TrovaGene: Trovera Liquid Biopsy Urine Test Results Positive (Revised)
Molecular diagnostic company, TrovaGene Inc. , recently presented clinical results demonstrating the effectiveness of its Trovera non-invasive test in detecting EGFR T790M mutations in the urine of patients with non-small cell lung cancer (NSCLC).
Built upon TrovaGene’s Precision Cancer Monitoring (PCM) platform, Trovera urine and blood-based EGFR, KRAS and BRAF CLIA and CAP-accredited tests are available to oncologists for the detection and monitoring of cancerous tumors.
The presentation demonstrated at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting showed that urine-based biopsy is an effective alternative to plasma or tissue-based tests when it comes to the detection of T790M mutations for targeted therapies.
The presentation showed that urine and plasma tests identified EGFR T790M mutations which tissue tests failed to spot. This is probably due to tumor heterogeneity or inadequate sample quality. Moreover, response rate to therapy, duration of response and progression-free survival of patients positive for T790M in urine was similar to patients who tested positive for T790M in plasma or tissue.
Lung cancer currently accounts for approximately 58% of TrovaGene’s total test volume. The company is planning to publish nine papers across a number of peer-reviewed journals in 2016.
TrovaGene also noted the publication of the first manuscript with a peer-reviewed paper in the oncology journal Cancer Discovery.
The first paper highlighted PCM platform’s ability to confirm BRAF V600E mutational status and to quantitatively assess changes in urinary circulating tumor DNA. The paper concluded that PCM can be used to determine response to novel therapy combining both a BRAF inhibitor and a MEK inhibitor to treat colorectal neuroendocrine tumors.
Of the remaining eight papers, TrovaGene has already submitted three and is in the process to submit another two in the near term.
The recent presentation validates TrovaGene’s claims over the effectiveness of its PCM technology. It is to be noted that the company’s non-invasive, cell-free technology is cost efficient. We feel that the technology can be ancillary to the current standard of tissue biopsy. It can also be performed in patients not fit for a tissue biopsy.
Zacks Rank & Key Picks
Currently, TrovaGene has a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader medical sector include IRadimed (IRMD - Free Report) , Masimo Corp (MASI - Free Report) and Exactech . While Masimo sports a Zacks Rank #1 (Strong Buy), both IRadimed and Exactech carry a Zacks Rank #2 (Buy).
(We have revised this article to correct a mistake. The previous version, published on Jun 7, should not be relied upon.)